The FDA Arthritis Advisory Committee has recommended the approval of CT-P13 (Remsima), a biosimilar version of the TNF inhibitor infliximab (Remicade), for ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis.
Dr. Paul I. Terasaki, Professor Emeritus of Surgery at the UCLA Geffen School of Medicine, passed away on January 25th, 2016 at the age of 86. Besides being one of the most important transplantation scientists, and establishing the largest transplantation registry of his time, Dr. Terasaki was responsible for discovering the linkage between HLA-B27 and ankylosing spondylitis in the U.S. in 1971.
By Elin Aslanyan
Just how common is spondyloarthritis globally? Is it more common in certain parts of the world and populations than others? And are we close to being able to estimate the number of people worldwide who have spondyloarthritis?
Join us on Saturday, February 6th, at 11:00 AM Pacific Time to learn about possible complications and comorbidities associated with spondyloarthritis.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.